<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03070730</url>
  </required_header>
  <id_info>
    <org_study_id>2011P000246</org_study_id>
    <secondary_id>R01HL059459</secondary_id>
    <nct_id>NCT03070730</nct_id>
  </id_info>
  <brief_title>Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist</brief_title>
  <official_title>A Double-Blinded, Placebo-Controlled Study To Assess Hemodynamic Changes, Orthostatic Tolerance, Out-Patient Fatigue And Quality Of Life In Neuropathic And Non-Neuropathic POTS Patients In Response To Adrenoreceptor Agonist And Antagonist</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the hypothesis that patients with non-neuropathic POTS
      will have different responsiveness than patients with neuropathic POTS to direct alpha-1
      adrenoreceptor agonist therapy (droxidopa) and to non-selective beta-adrenoreceptor
      antagonist therapy (atenolol).

      The specific goal of this protocol is to investigate the effect of atenolol and droxidopa on
      cardiovascular autonomic functions such as cardiovagal control, sympathetic nerve activity,
      and sympathetic vascular transduction, systemic hemodynamic response to orthostatic stress
      and on the quality of life in neuropathic and non-neuropathic patients with postural
      tachycardia syndrome (POTS).

      Standardized tests are used to assess cardiovagal control function, sympathetic nerve
      activity, sympathetic vascular transduction, systemic hemodynamic response to head-up tilt
      test and standardized questionnaires to assess the quality of life in patients with POTS.

      The cardiovagal, sympathetic and hemodynamic measurements are performed after and during drug
      administration. To control the effect of medications placebo is used on separate testing
      visits. The order of drugs and placebo is randomized.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pathophysiological basis of postural tachycardia syndrome (POTS) is not well elucidated.
      The most widely recognized primary cause of POTS is a &quot;restricted&quot; or &quot;selective&quot; peripheral
      neuropathy - neuropathic POTS. Several lines of evidence point to a restricted peripheral
      neuropathy, specifically sympathetic denervation in the lower hemibody, as a cause of POTS.
      These include venous denervation, impaired distal sudomotor dysfunction, lower norepinephrine
      spillover in the legs than the arms. However, not all POTS patients have peripheral
      neuropathy. Proposed pathogenic etiologies for non-neuropathic POTS include deconditioning,
      low-grade inflammation and oxidative stress. Neuropathic POTS is present in 33% of patients
      while non-neuropathic POTS is present in 67% of patients.

      The most frequent neuropathic feature in the neuropathic POTS group is decreased sweat output
      measured by quantitative sudomotor axon reflex test. Headache and gastrointestinal symptoms
      (such as abdominal pain, bloating, nausea and constipation) are also more prevalent in the
      neuropathic than in the non-neuropathic POTS group, suggesting more global differences
      between the two populations.

      In relation to the ambiguous pathophysiological basis, there is no definitive treatment for
      POTS. There are reports of improvements in hemodynamic measures and symptoms of orthostatic
      tolerance with pharmacologic agents that include intravenous saline, intravenous
      phenylephrine, midodrine, octreotide, erythropoietin, pyridostigmine, and betablockade. The
      therapy is however frequently disappointing. Furthermore, there are no reported long-term
      studies of medications to treat POTS and there are no reports of the effects of any
      intervention on fatigue or quality of life.

      The most widely used agents to treat POTS, the alpha-adrenoreceptor agonist midodrine, and
      the beta blockers, paradoxically have agonistic and antagonistic effects on the autonomic
      nervous system. Responses to these drugs are inconsistent and there are no delineated
      predictors of the response in POTS patients.

      The comparison of therapeutic interventions in this protocol are based on the rationale that
      while alpha-adrenoreceptor agonists are thought to be more effective in neuropathic POTS - a
      disorder characterized by a compensatory increase in sympathetic outflow in which
      sympatholysis may be counterproductive, beta-adrenoreceptor antagonists are thought to be
      more effective in non-neuropathic POTS - a disorder that could be characterized by increased
      central sympathetic outflow due to impaired sympathetic inhibition.

      This protocol uses droxidopa, which is converted to direct adrenoreceptor agonist,
      norepinephrine. The protocol also uses beta-adrenoreceptor antagonist, the non-selective
      atenolol.

      This is a randomized, double-blind, placebo-controlled, cross-over experimental study with
      three trial arms, according to the two medications (droxidopa and atenolol) and the placebo.
      The trial is performed in the Center for Autonomic and Peripheral Nerve Disorders at the Beth
      Israel Deaconess Medical Center.

      The study consists of 10 visits:

        -  screening visit,

        -  testing days to define drug sensitivity

        -  classification day

        -  autonomic testing visits

        -  follow-up visits

      Screening visit (Visit 1) includes

        -  Consenting procedure

        -  Review of medical history

        -  Review of all current medications, prescription and over the counter

        -  Physical and neurological examinations

        -  Measure height, weight, temperature and vital signs

        -  12-lead ECG

        -  Baseline autonomic tests

        -  Blood labs

        -  Serum pregnancy testing for women of childbearing potential

        -  Patients are able to take PO medications

      Drug Sensitivity Visit (Visit 2 and 3) On the first visit, patients receive one 100 mg
      droxidopa while on the second visit patients receive one 300 mg test dose of droxidopa to
      define their response to the drug. The drug administration is preceded and followed by heart
      rate and blood pressure measurements and side effect monitoring. The two consecutive visits
      are made within a period of 3 days. The goal of sensitivity visit is to determine if a
      patient has any sign of denervation supersensitivity in response to droxidopa. The patient is
      considered to have denervation supersensitivity if systolic blood pressure is greater than
      180 mmHg or diastolic blood pressure is greater than 110 mmHg after 3 minutes of standing or
      after 5 minutes of sitting or the patient is unable to tolerate the side effects believed to
      be related to the drug.

      Patient classification visit (Visit 4) includes

        -  Quantitative Direct and Indirect testing of Sudomotor Function (QDIRT)

        -  Quantitative Sudomotor Axon Reflex Testing (QSART)

        -  Quantitative Sensory Testing (QST)

        -  Punch skin biopsy

        -  Questionnaires (Chronic Fatigue Screening Form, Fatigue Severity Scale, Chalder Fatigue
           Questionnaire, etc., see Questionnaires section)

      Autonomic Evaluation Visits (Visit 5, 7 and 9) include

        -  Urine pregnancy test for women of child-bearing potential

        -  Setup and instrumentation

        -  Blood draw for hormones and catecholamines (Visit 5 only)

        -  Microneurography procedure

        -  Drug/placebo administration

        -  Deep breathing test

        -  Paced breathing test

        -  Modified Oxford test

        -  Sympathetic transduction

        -  Static exercise

        -  Tilt table test

      Primary outcome measure of autonomic evaluation visit is maximum postural tachycardia while
      secondary outcome measure of autonomic evaluation visit are blood pressure, heart rate,
      vascular resistance, muscle sympathetic nerve activity.

      Follow-up testing visits (Visit 6, 8 and 10) include

        -  Medical history

        -  Physical examination

        -  Vital signs

        -  EKG

        -  Blood pressure measurement

        -  Tilt table test

      Primary outcome measure of follow-up testing visits is the fatigue score on the Chalder
      Fatigue questionnaire while secondary outcome measures of follow-up testing visits are the
      scores on the physical functioning subscale of the SF-36 questionnaire, 7 item patient global
      impression of change, the Hospital Anxiety and Depression Scales, the Checklist Individual
      Strength (CIS), Multidimensional Fatigue Inventory (MFI), the Fatigue Severity Scale, the
      EuroQOL, the HADS and anxiety scores. The Orthostatic Intolerance Questionnaire - a unique
      validated questionnaire is used to assess orthostatic intolerance symptoms and quality of
      life-related to orthostatic intolerance.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment was slow and subjects declined participation after signing the ICF.
  </why_stopped>
  <start_date type="Actual">August 15, 2011</start_date>
  <completion_date type="Actual">July 28, 2014</completion_date>
  <primary_completion_date type="Actual">December 18, 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The study design is a &quot;double-dummy&quot; design. While during two of the three trial arms the patients take an active study drug and a placebo, there is also an arm where patients take only placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Maximal Postural Tachycardia During Tilt</measure>
    <time_frame>Up to 3 days after randomization</time_frame>
    <description>Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change Maximal Postural Tachycardia During Tilt</measure>
    <time_frame>2 weeks after first intervention</time_frame>
    <description>Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change Maximal Postural Tachycardia During Tilt</measure>
    <time_frame>2 weeks after second intervention</time_frame>
    <description>Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline</measure>
    <time_frame>up to 3 days after randomization</time_frame>
    <description>A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline</measure>
    <time_frame>2 weeks after first intervention</time_frame>
    <description>A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline</measure>
    <time_frame>2 weeks after second intervention</time_frame>
    <description>A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Pressure From Baseline</measure>
    <time_frame>1 week after first intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Pressure From Baseline</measure>
    <time_frame>1 week after second intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Pressure From Baseline</measure>
    <time_frame>1 week after third intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Heart Rate From Baseline</measure>
    <time_frame>1 week after first intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Heart Rate From Baseline</measure>
    <time_frame>1 week after second intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Heart Rate From Baseline</measure>
    <time_frame>1 week after third intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vascular Resistance From Baseline</measure>
    <time_frame>1 week after first intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vascular Resistance From Baseline</measure>
    <time_frame>1 week after second intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vascular Resistance From Baseline</measure>
    <time_frame>1 week after third intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Muscle Sympathetic Nerve Activity From Baseline</measure>
    <time_frame>1 week after first intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Muscle Sympathetic Nerve Activity From Baseline</measure>
    <time_frame>1 week after second intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Muscle Sympathetic Nerve Activity From Baseline</measure>
    <time_frame>1 week after third intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning-SF-36 Q From Baseline</measure>
    <time_frame>1 week after first intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning-SF-36 Q From Baseline</measure>
    <time_frame>1 week after second intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning-SF-36 Q From Baseline</measure>
    <time_frame>1 week after third intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline</measure>
    <time_frame>1 week after first intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better&quot; to &quot;very much worse&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline</measure>
    <time_frame>1 week after second intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better&quot; to &quot;very much worse&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline</measure>
    <time_frame>1 week after third intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better&quot; to &quot;very much worse&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning- HADS From Baseline</measure>
    <time_frame>1 week after first intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning- HADS From Baseline</measure>
    <time_frame>1 week after second intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning- HADS From Baseline</measure>
    <time_frame>1 week after third intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning-CIS From Baseline</measure>
    <time_frame>1 week after first intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning-CIS From Baseline</measure>
    <time_frame>1 week after second intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning-CIS From Baseline</measure>
    <time_frame>1 week after third intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning-MFI From Baseline</measure>
    <time_frame>1 week after first intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning-MFI From Baseline</measure>
    <time_frame>1 week after second intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning-MFI From Baseline</measure>
    <time_frame>1 week after third intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning-FSS From Baseline</measure>
    <time_frame>1 week after first intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning-FSS From Baseline</measure>
    <time_frame>1 week after second intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning-FSS From Baseline</measure>
    <time_frame>1 week after third intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning-EuroQOL From Baseline</measure>
    <time_frame>1 week after first intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning-EuroQOL From Baseline</measure>
    <time_frame>1 week after second intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning-EuroQOL From Baseline</measure>
    <time_frame>1 week after third intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning-OI From Baseline</measure>
    <time_frame>1 week after first intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning-OI From Baseline</measure>
    <time_frame>1 week after second intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Functioning-OI From Baseline</measure>
    <time_frame>1 week after third intervention</time_frame>
    <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Postural Orthostatic Tachycardia Syndrome</condition>
  <condition>Orthostatic Intolerance</condition>
  <arm_group>
    <arm_group_label>Atenolol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebos</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Droxidopa</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Droxidopa</intervention_name>
    <description>Droxidopa: 100 mg or 300 mg t.i.d</description>
    <arm_group_label>Atenolol</arm_group_label>
    <arm_group_label>Droxidopa</arm_group_label>
    <other_name>Northera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <description>Atenolol: 50 mg Q.D.</description>
    <arm_group_label>Atenolol</arm_group_label>
    <arm_group_label>Droxidopa</arm_group_label>
    <other_name>Tenormin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo: t.i.d</description>
    <arm_group_label>Atenolol</arm_group_label>
    <arm_group_label>Placebos</arm_group_label>
    <arm_group_label>Droxidopa</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CDC criteria for chronic fatigue syndrome

          -  Evidence of postural tachycardia syndrome with symptoms of orthostatic intolerance

        Exclusion Criteria:

          -  Pregnant or lactating females. The administration of droxidopa is harmful to the fetus

          -  Concomitant therapy with anticholinergic, alpha-, and beta-adrenergic antagonists or
             other medications that affect autonomic function

          -  Clinically significant coronary artery, cerebrovascular or peripheral vascular disease

          -  Cardiac arrhythmias

          -  Systemic illness that might affect autonomic function such as congestive heart
             failure, hypertension, renal, pulmonary, and hepatic disease, anemia, malignancies,
             thyroid disease, and alcoholism

          -  Severe depression, severe anxiety disorder (score of on the Beck Depression Inventory
             &gt; 29 or score on the Beck Anxiety Inventory of â‰¥ 36) or psychosis

          -  Antidepressant treatment by MAO inhibitors within 2 weeks before the study

          -  Glaucoma

          -  Liver disease

          -  Subjects with a history of reaction to local anesthetic will be excluded from the
             study

          -  Subjects who have a history of any bleeding disorders or significantly impaired wound
             healing will be excluded. Subjects who are using any medications such as Coumadin or
             Plavix will be also excluded

          -  Subjects who are currently enrolled in any other studies using investigational
             products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy Freeman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Autonomic and Peripheral Nerve Disorders - Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jacob G, Biaggioni I. Idiopathic orthostatic intolerance and postural tachycardia syndromes. Am J Med Sci. 1999 Feb;317(2):88-101. Review.</citation>
    <PMID>10037112</PMID>
  </reference>
  <reference>
    <citation>Karas B, Grubb BP, Boehm K, Kip K. The postural orthostatic tachycardia syndrome: a potentially treatable cause of chronic fatigue, exercise intolerance, and cognitive impairment in adolescents. Pacing Clin Electrophysiol. 2000 Mar;23(3):344-51.</citation>
    <PMID>10750135</PMID>
  </reference>
  <reference>
    <citation>Stewart JM. Autonomic nervous system dysfunction in adolescents with postural orthostatic tachycardia syndrome and chronic fatigue syndrome is characterized by attenuated vagal baroreflex and potentiated sympathetic vasomotion. Pediatr Res. 2000 Aug;48(2):218-26.</citation>
    <PMID>10926298</PMID>
  </reference>
  <reference>
    <citation>Schondorf R, Low PA. Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia? Neurology. 1993 Jan;43(1):132-7.</citation>
    <PMID>8423877</PMID>
  </reference>
  <reference>
    <citation>Jacob G, Costa F, Shannon JR, Robertson RM, Wathen M, Stein M, Biaggioni I, Ertl A, Black B, Robertson D. The neuropathic postural tachycardia syndrome. N Engl J Med. 2000 Oct 5;343(14):1008-14.</citation>
    <PMID>11018167</PMID>
  </reference>
  <reference>
    <citation>Streeten DH. Pathogenesis of hyperadrenergic orthostatic hypotension. Evidence of disordered venous innervation exclusively in the lower limbs. J Clin Invest. 1990 Nov;86(5):1582-8.</citation>
    <PMID>2243132</PMID>
  </reference>
  <reference>
    <citation>Low PA, Novak V, Spies JM, Novak P, Petty GW. Cerebrovascular regulation in the postural orthostatic tachycardia syndrome (POTS). Am J Med Sci. 1999 Feb;317(2):124-33. Review.</citation>
    <PMID>10037116</PMID>
  </reference>
  <reference>
    <citation>Freeman R, Lirofonis V, Farquhar WB, Risk M. Limb venous compliance in patients with idiopathic orthostatic intolerance and postural tachycardia. J Appl Physiol (1985). 2002 Aug;93(2):636-44.</citation>
    <PMID>12133874</PMID>
  </reference>
  <reference>
    <citation>Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I, Blakely RD, Robertson D. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med. 2000 Feb 24;342(8):541-9.</citation>
    <PMID>10684912</PMID>
  </reference>
  <reference>
    <citation>Al-Shekhlee A, Lindenberg JR, Hachwi RN, Chelimsky TC. The value of autonomic testing in postural tachycardia syndrome. Clin Auton Res. 2005 Jun;15(3):219-22.</citation>
    <PMID>15944872</PMID>
  </reference>
  <reference>
    <citation>Stewart JM, Munoz J, Weldon A. Clinical and physiological effects of an acute alpha-1 adrenergic agonist and a beta-1 adrenergic antagonist in chronic orthostatic intolerance. Circulation. 2002 Dec 3;106(23):2946-54.</citation>
    <PMID>12460877</PMID>
  </reference>
  <reference>
    <citation>Gordon VM, Opfer-Gehrking TL, Novak V, Low PA. Hemodynamic and symptomatic effects of acute interventions on tilt in patients with postural tachycardia syndrome. Clin Auton Res. 2000 Feb;10(1):29-33.</citation>
    <PMID>10750641</PMID>
  </reference>
  <reference>
    <citation>Freitas J, Santos R, Azevedo E, Costa O, Carvalho M, de Freitas AF. Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone. Clin Auton Res. 2000 Oct;10(5):293-9.</citation>
    <PMID>11198485</PMID>
  </reference>
  <reference>
    <citation>Gibbons CH, Vernino SA, Kaufmann H, Freeman R. L-DOPS therapy for refractory orthostatic hypotension in autoimmune autonomic neuropathy. Neurology. 2005 Oct 11;65(7):1104-6.</citation>
    <PMID>16217067</PMID>
  </reference>
  <reference>
    <citation>Low PA, Opfer-Gehrking TL, Textor SC, Benarroch EE, Shen WK, Schondorf R, Suarez GA, Rummans TA. Postural tachycardia syndrome (POTS). Neurology. 1995 Apr;45(4 Suppl 5):S19-25. Review.</citation>
    <PMID>7746369</PMID>
  </reference>
  <reference>
    <citation>Grubb BP, Kosinski DJ, Boehm K, Kip K. The postural orthostatic tachycardia syndrome: a neurocardiogenic variant identified during head-up tilt table testing. Pacing Clin Electrophysiol. 1997 Sep;20(9 Pt 1):2205-12.</citation>
    <PMID>9309745</PMID>
  </reference>
  <reference>
    <citation>Sandroni P, Opfer-Gehrking TL, McPhee BR, Low PA. Postural tachycardia syndrome: clinical features and follow-up study. Mayo Clin Proc. 1999 Nov;74(11):1106-10.</citation>
    <PMID>10560597</PMID>
  </reference>
  <reference>
    <citation>Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83.</citation>
    <PMID>1593914</PMID>
  </reference>
  <reference>
    <citation>Paffenbarger RS Jr, Blair SN, Lee IM, Hyde RT. Measurement of physical activity to assess health effects in free-living populations. Med Sci Sports Exerc. 1993 Jan;25(1):60-70.</citation>
    <PMID>8423758</PMID>
  </reference>
  <reference>
    <citation>Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70.</citation>
    <PMID>6880820</PMID>
  </reference>
  <reference>
    <citation>Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995 Apr;39(3):315-25.</citation>
    <PMID>7636775</PMID>
  </reference>
  <reference>
    <citation>Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989 Oct;46(10):1121-3.</citation>
    <PMID>2803071</PMID>
  </reference>
  <reference>
    <citation>EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199-208.</citation>
    <PMID>10109801</PMID>
  </reference>
  <reference>
    <citation>Moss-Morris R, Sharon C, Tobin R, Baldi JC. A randomized controlled graded exercise trial for chronic fatigue syndrome: outcomes and mechanisms of change. J Health Psychol. 2005 Mar;10(2):245-59.</citation>
    <PMID>15723894</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2012</study_first_submitted>
  <study_first_submitted_qc>February 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2017</study_first_posted>
  <results_first_submitted>April 12, 2017</results_first_submitted>
  <results_first_submitted_qc>April 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2017</results_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Roy Freeman, MD</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Tachycardia</keyword>
  <keyword>orthostatic symptoms</keyword>
  <keyword>autonomic reflex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Orthostatic Intolerance</mesh_term>
    <mesh_term>Postural Orthostatic Tachycardia Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Droxidopa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>NIH Grant Policy on Sharing of Unique Research Resources including the Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants that were enrolled in the study were excluded from the study because they either did not meet eligibility criteria or decided not to participate.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atenolol</title>
          <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
        </group>
        <group group_id="P2">
          <title>Placebos</title>
          <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
        </group>
        <group group_id="P3">
          <title>Droxidopa</title>
          <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants that were enrolled in the study were not randomized. They did not meet eligibility criteria, or decided not to participate.</population>
      <group_list>
        <group group_id="B1">
          <title>Atenolol</title>
          <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
        </group>
        <group group_id="B2">
          <title>Placebos</title>
          <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
        </group>
        <group group_id="B3">
          <title>Droxidopa</title>
          <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Maximal Postural Tachycardia During Tilt</title>
        <description>Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test.</description>
        <time_frame>Up to 3 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Maximal Postural Tachycardia During Tilt</title>
          <description>Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change Maximal Postural Tachycardia During Tilt</title>
        <description>Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test.</description>
        <time_frame>2 weeks after first intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change Maximal Postural Tachycardia During Tilt</title>
          <description>Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change Maximal Postural Tachycardia During Tilt</title>
        <description>Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test.</description>
        <time_frame>2 weeks after second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change Maximal Postural Tachycardia During Tilt</title>
          <description>Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline</title>
        <description>A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue.</description>
        <time_frame>up to 3 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline</title>
          <description>A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline</title>
        <description>A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue.</description>
        <time_frame>2 weeks after first intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline</title>
          <description>A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline</title>
        <description>A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue.</description>
        <time_frame>2 weeks after second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline</title>
          <description>A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Pressure From Baseline</title>
        <time_frame>1 week after first intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Pressure From Baseline</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Pressure From Baseline</title>
        <time_frame>1 week after second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Pressure From Baseline</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Pressure From Baseline</title>
        <time_frame>1 week after third intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Pressure From Baseline</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Heart Rate From Baseline</title>
        <time_frame>1 week after first intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Heart Rate From Baseline</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Heart Rate From Baseline</title>
        <time_frame>1 week after second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Heart Rate From Baseline</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Heart Rate From Baseline</title>
        <time_frame>1 week after third intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Heart Rate From Baseline</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Vascular Resistance From Baseline</title>
        <time_frame>1 week after first intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vascular Resistance From Baseline</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Vascular Resistance From Baseline</title>
        <time_frame>1 week after second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vascular Resistance From Baseline</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Vascular Resistance From Baseline</title>
        <time_frame>1 week after third intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vascular Resistance From Baseline</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Muscle Sympathetic Nerve Activity From Baseline</title>
        <time_frame>1 week after first intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Muscle Sympathetic Nerve Activity From Baseline</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Muscle Sympathetic Nerve Activity From Baseline</title>
        <time_frame>1 week after second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Muscle Sympathetic Nerve Activity From Baseline</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Muscle Sympathetic Nerve Activity From Baseline</title>
        <time_frame>1 week after third intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Muscle Sympathetic Nerve Activity From Baseline</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning-SF-36 Q From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire.</description>
        <time_frame>1 week after first intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning-SF-36 Q From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning-SF-36 Q From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire.</description>
        <time_frame>1 week after second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning-SF-36 Q From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning-SF-36 Q From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire.</description>
        <time_frame>1 week after third intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning-SF-36 Q From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better&quot; to &quot;very much worse&quot;.</description>
        <time_frame>1 week after first intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better&quot; to &quot;very much worse&quot;.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better&quot; to &quot;very much worse&quot;.</description>
        <time_frame>1 week after second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better&quot; to &quot;very much worse&quot;.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better&quot; to &quot;very much worse&quot;.</description>
        <time_frame>1 week after third intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better&quot; to &quot;very much worse&quot;.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning- HADS From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales.</description>
        <time_frame>1 week after first intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning- HADS From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning- HADS From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales.</description>
        <time_frame>1 week after second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning- HADS From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning- HADS From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales.</description>
        <time_frame>1 week after third intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning- HADS From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning-CIS From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS).</description>
        <time_frame>1 week after first intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning-CIS From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS).</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning-CIS From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS).</description>
        <time_frame>1 week after second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning-CIS From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS).</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning-CIS From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS).</description>
        <time_frame>1 week after third intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning-CIS From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS).</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning-MFI From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI).</description>
        <time_frame>1 week after first intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning-MFI From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI).</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning-MFI From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI).</description>
        <time_frame>1 week after second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning-MFI From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI).</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning-MFI From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI).</description>
        <time_frame>1 week after third intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning-MFI From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI).</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning-FSS From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale.</description>
        <time_frame>1 week after first intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning-FSS From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning-FSS From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale.</description>
        <time_frame>1 week after second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning-FSS From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning-FSS From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale.</description>
        <time_frame>1 week after third intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning-FSS From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning-EuroQOL From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL.</description>
        <time_frame>1 week after first intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning-EuroQOL From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning-EuroQOL From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL.</description>
        <time_frame>1 week after second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning-EuroQOL From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning-EuroQOL From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL.</description>
        <time_frame>1 week after third intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning-EuroQOL From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning-OI From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire.</description>
        <time_frame>1 week after first intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning-OI From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning-OI From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire.</description>
        <time_frame>1 week after second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning-OI From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Physical Functioning-OI From Baseline</title>
        <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire.</description>
        <time_frame>1 week after third intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
          </group>
          <group group_id="O3">
            <title>Droxidopa</title>
            <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Physical Functioning-OI From Baseline</title>
          <description>Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Atenolol</title>
          <description>In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
        </group>
        <group group_id="E2">
          <title>Placebos</title>
          <description>In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d</description>
        </group>
        <group group_id="E3">
          <title>Droxidopa</title>
          <description>In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was terminated early due to difficulties in the recruitment process. Subjects were found to be ineligible, or decided not to participate in the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Roy Freeman</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>617-632-8454</phone>
      <email>rfreeman@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

